TREATMENT OF DIABETES WITH ROSIGLITAZONE AND INSULIN

摘要

1. A composition comprising from 2 to 12 mg 5-[[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidyl-2,4-dione of Compound (I) or a pharmaceutically acceptable form and insulin for the treatment of diabetes of type 2 and conditions associated with diabetes type 2. 2. The composition according to claim 1, comprising from 2 to 4 mg, from 4 to 8 mg or from 8 to 12 mg of Compound (I) or a pharmaceutically acceptable form. 3. The composition according to claim 1 or 2, comprising from 2 to 4 mg of Compound (I) or a pharmaceutically acceptable form. 4. The composition according to claim 1 or 2, comprising from 4 to 8 mg of Compound (I) or a pharmaceutically acceptable form. 5. The composition according to claim 1 or 2, comprising from 8 to 12 mg of Compound (I) or a pharmaceutically acceptable form. 6. The composition according to any one of claims 1-3, comprising 2 mg of Compound (I) or a pharmaceutically acceptable form. 7. The composition according to any one of claims 1-4, comprising 4 mg of Compound (I) or a pharmaceutically acceptable form. 8. The composition according to any one of claims 1, 2, 4 and 5, comprising 8 mg of Compound (I) or a pharmaceutically acceptable form. 9. The composition according to any one of claims 1-8, wherein Compound (I) or pharmaceutically acceptable form thereof and insulin are prepared in the form of one pharmaceutical composition dosage. 10. The composition according to any one of claims 1-9, wherein Compound (I) or pharmaceutically acceptable form thereof and insulin are represented in the form of separate pharmaceutical compositions. 11. A pharmaceutical composition comprising from 2 to 12 mg 5-[[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidyl-2,4-dione of Compound (I) or a pharmaceutically acceptable form and insulin for the treatment of diabetes of type 2 and conditions associated with diabetes type 2. 12. Use from 2 to 12 mg 5-[[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidyl-2,4-dione of Compound (I) or a pharmaceutically acceptable form and insulin for the manufacturing a medicament for use in the treatment of diabetes of type 2 and conditions associated with diabetes type 2. 13. Use from 2 to 12 mg 5-[[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidyl-2,4-dione of Compound (I) or a pharmaceutically acceptable form and insulin for the manufacturing a medicament for use with insulin in the treatment of diabetes of type 2 and conditions associated with diabetes type 2. 14. Use insulin for manufacturing a medicament for use from 2 to 12 mg 5-[[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidyl-2,4-dione of Compound (I) or a pharmaceutically acceptable form for the treatment of diabetes of type 2 and conditions associated with diabetes type 2.